Ursula A. Matulonis, MD | Authors

August 16, 2020

The expert from Dana-Farber Cancer Institute spoke about the study of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

August 08, 2020

The expert from the Dana-Farber Cancer Institute discussed the study findings which assessed the use of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

July 17, 2020

The expert from Dana-Farber Cancer Institute discussed the study design and inclusion criteria for this study of pembrolizumab in patients with advanced recurrent ovarian cancer.

June 20, 2020

The study results indicated that pembrolizumab monotherapy was associated with modest antitumor activity in patients with recurrent advanced ovarian cancer.

June 10, 2020

The Dana-Farber Cancer Institute expert discussed pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

July 15, 2010

Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with approximately 15,000 deaths per year. Platinum/taxane doublets have long been considered the standard treatment regimen for advanced-stage disease; however, recent studies have sought to improve on the outcome from this therapy. Intraperitoneal (IP) chemotherapy has been shown to yield superior progression-free survival (PFS) and overall survival (OS); however, logistical problems and toxicities have limited more widespread adoption. Recent studies have also suggested that a “dose-dense” schedule of paclitaxel in combination with carboplatin may result in improved outcomes, and the impact of biological therapies in the first-line setting is under active investigation. In the setting of recurrent disease, preliminary results suggest that novel doublet regimens such as carboplatin and pegylated liposomal doxorubicin may have similar activity to standard platinum/taxane doublets while carrying a reduced risk of allergic reactions. Additionally, targeted therapy remains an active area of investigation, with evidence of activity from agents such as PARP inhibitors, anti-angiogenics, and PI3 kinase inhibitors. Here, we review recent advances in our understanding of ovarian cancer and its treatment in both the newly diagnosed and recurrent settings.

May 01, 1999

Drs. Fornier, Munster, and Seidman provide a comprehensive update of the management of metastatic breast cancer. They review the latest innovations in both chemotherapy and hormonal therapy for advanced disease, and demonstrate just how

May 01, 1996

Molecular oncology, as it relates to cancer formation, growth, metastasis, and treatment, is a rapidly progressing and exciting field. Its forward movement is so fast that even scientific journals, because of publication delays, are unable to keep readers informed in a timely manner. What, therefore, is the role of a textbook on molecular oncology?